Therapix gains rights to synthetic cannabinoids from Hebrew University

Therapix Biosciences Ltd. (Tel Aviv:TRPX; NASDAQ:TRPX) received non-exclusive rights to IP for two synthetic cannabinoid compounds from Yissum Research Development Company Ltd., the Hebrew University of Jerusalem's technology transfer arm.

Therapix said Yissum retains ownership of the IP. Financial details were not disclosed. Yissum did not respond to inquiries...